Verastem Stock Price

-0.07 (-5.65%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Verastem Inc VSTM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.07 -5.65% 1.17 19:57:27
Close Price Low Price High Price Open Price Previous Close
1.20 1.15 1.22 1.20 1.24
Bid Price Ask Price Spread News
1.17 1.19 0.02 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6,195 2,960,691 $ 1.17 $ 3,462,686 2,434,578 0.83 - 4.73
Last Trade Time Type Quantity Stock Price Currency
19:50:39 12 $ 1.17 USD

Verastem Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 198.35M 169.53M 150.64M $ 17.46M $ - -2.01 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Verastem News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VSTM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.251.321.141.223,277,960-0.08-6.4%
1 Month1.241.421.141.282,375,690-0.07-5.65%
3 Months1.491.751.081.333,319,178-0.32-21.48%
6 Months1.772.071.081.625,302,099-0.60-33.9%
1 Year1.234.730.831.814,203,310-0.06-4.88%
3 Years3.7810.350.833.092,676,094-2.61-69.05%
5 Years1.8410.350.833.071,815,047-0.67-36.41%

Verastem Description

Verastem Inc is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.